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Glioblastomas, (grade 4 astrocytomas), are aggressive primary brain tumors characterized
by histopathological heterogeneity. High-resolution sequencing technologies have shown
that these tumors also feature significant inter-tumoral molecular heterogeneity. Molecu-
lar subtyping of these tumors has revealed several predictive and prognostic biomarkers.
However, intra-tumoral heterogeneity may undermine the use of single biopsy analysis
for determining tumor genotype and has implications for potential targeted therapies.
The clinical relevance and theories of tumoral molecular heterogeneity in glioblastoma are
discussed.
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INTRODUCTION
Malignant gliomas are the most common intrinsic primary brain
tumors in adults. Despite advances in neurosurgery, chemother-
apy, and radiation, the median survival for the most aggressive
tumors, glioblastoma remains less than 2 years. Although glioblas-
tomas share common histological features, at a molecular level
these tumors are highly variable from patient to patient and
within the same tumor can display significant regional heterogene-
ity. Molecular analysis of a single biopsy specimen for diagnosis
and determination of therapeutic options has profound clinical
implications for targeted therapeutic treatment strategies until
more is known about molecular pathways and driver mutations in
glioblastoma.
HISTOLOGICAL DIAGNOSIS AND CLASSIFICATION OF MALIGNANT
GLIOMA SUBTYPES
Histopathology remains the gold standard for the diagnosis and
classification of gliomas and currently determines adjuvant ther-
apy. Gliomas include astrocytomas (with cells that resemble astro-
cytes), oligodendrogliomas (predominantly of cells that resem-
ble oligodendrocytes), and mixed oligoastrocytomas. The current
2007 World Health Organization (WHO) classification of astro-
cytoma (including glioblastoma) depends on cellular morphology
to determine tumor grade, focusing on the presence or absence
of nuclear atypia, mitotic activity, microvascular proliferation,
and necrosis (1). This histopathological classification system is
fraught with error, and inter-observer subjectivity is common (2).
Regional heterogeneity is common, as reflected by the original
name for WHO Grade IV astrocytoma, glioblastoma multiforme
(GBM) (3). Pathological diagnosis is based on the area of the
highest grade visible in multiple sections, even though less aggres-
sive areas may also be present in the specimen. Tumors with the
same histopathological classification also exhibit widely variable
clinical presentation, magnetic resonance imaging (MRI) features,
response to therapy and outcome. Primary glioblastoma most
commonly presents de novo in elderly patients, typically with a
short clinical history. In contrast, secondary glioblastoma pro-
gresses from lower grade astrocytic lesions, occur in younger
patients, are more likely to be located in the frontal lobes, and
have a significantly improved outcome (4). Molecular analyses
show they arise from different genomic alterations, which may
influence response to therapy (5).
MOLECULAR CLASSIFICATION OF GLIOBLASTOMA
SUBTYPES
Recent large-scale genomic analyses have identified extensive inter-
patient heterogeneity, further refining histopathological classifica-
tion of this disease. The Cancer Genome Atlas (TCGA) project
and others (5–7) have shown that glioblastoma can be subclas-
sified into at least four molecular subtypes, featuring distinct
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genetic, epigenetic, and transcriptional alterations (5, 8). Tumor
variants can be classified on the basis of somatic mutations
in isocitrate dehydrogenase (IDH) 1/2 and TP53; transcriptional
signature (classical, mesenchymal, neural, or proneural); copy
number variation, including co-deletion of chromosomes 1p and
19q; and amplification or mutation of the epidermal growth fac-
tor receptor (EGFR) and increased DNA hypermethylation of
promoter-associated CpG islands (Figure 1) (5–10).
In particular, the TCGA subtypes have been increasingly
applied for their prognostic ability and ease of testing for a single
typical molecular alteration associated with that subtype, namely
IDH1/2 mutation (proneural), EGFR amplification (classical),
or Neurofibromin 1(NF1) loss (mesenchymal) (5). Also associ-
ated with the proneural subtype are 1p and 19q co-deletion,
TP53 mutations, and platelet-derived growth factor receptor, alpha
polypeptide (PDGFRA) amplification. These and other molecular
aberrations associated with the transcriptional subtypes are shown
in Figure 1.
The identified molecular heterogeneity may underlie differ-
ences in patient sensitivity to therapy and prognosis. In current
clinical practice, standard histopathology is complemented by
molecular testing generally performed on single tumor biopsies.
FIGURE 1 | Molecular classification of major glioblastoma subtypes and
correlation with treatment response and outcome. IDH1/2 mutations are
major prognostic biomarkers, stratifying primary and secondary pathways of
gliomagenesis. Primary glioblastoma features a high frequency of TERT
mutations, whereas IDH1/2 mutated glioma (including secondary
glioblastoma and low grade glioma) may be further subdivided on the basis of
co-mutations in either ATRX and TP53 or CIC and FUBP1, occurring at high
frequency in astrocytic or oligodendroglial tumor subtypes. Co-deletion of 1p
and 19q, a marker of enhanced chemosensitivity, also clusters with mutations
in CIC and FUBP1. Primary glioblastomas display classical, mesenchymal, and
neural phenotypes, whereas secondary glioblastomas tend to display a
proneural phenotype that shifts toward a mesenchymal phenotype with
recurrence. The significantly improved outcome of the proneural subset is due
to the G-CIMP phenotype, established by IDH1/2-mediated metabolic
reprogramming of the epigenome. Primary glioblastomas and a subset of
proneural tumors are glioma-CpG island hypermethylator phenotype (G-CIMP)
negative, and a large proportion are MGMT unmethylated. Both classical and
mesenchymal transcriptional subtypes benefit from concurrent
chemoradiotherapy, however, MGMT status is only predictive of treatment
response in the classical subset.
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Key biomarkers commonly assessed include IDH1/2 mutations,
O6-methylguanine DNA methyltransferase (MGMT ) promoter
methylation, co-deletion of 1p and 19q, and EGFR amplifica-
tion/truncation.
MOLECULAR BIOMARKERS IN GLIOBLASTOMA
IDH1/2 mutation status
Somatic mutations in IDH1/2 are routinely screened by Sanger
sequencing and/or immunohistochemistry. These heterozygous
point mutations occur commonly at arginine residues, at codon
132 of IDH1 and at codon 172 of IDH2, and are definitive markers
of secondary glioblastoma and a significantly improved progno-
sis (9). IDH1 mutations occur at high frequency in WHO grade
II and III astrocytoma (>80% of cases), precursor lesions of
secondary glioblastoma, whereas IDH2 mutations occur largely
in oligodendroglial tumors, with much lower frequency. Both
alterations are rare in de novo glioblastoma (occurring in <5%
of cases). IDH-mutant glioblastoma occurs predominantly in
the frontal lobe, whereas the anatomical distribution of IDH -
wildtype glioblastoma is more heterogeneous (11). More recently,
loss of alpha-thalassemia/mental retardation syndrome X-linked
(ATRX) has been shown to further refine IDH -mutant astro-
cytic tumors with IDH/ATRX mutant-tumors carrying a more
favorable prognosis (10).
In addition to its role as a biomarker, IDH1 mutation may
provide the basis for a targeted immunotherapy. A peptide con-
taining mutant (R132H) IDH1 has been shown to be immuno-
genic suggesting the potential for a mutation-specific vaccine for
IDH1-mutant gliomas (12).
In both low- and high-grade gliomas with IDH mutations,
combined loss of the short arm of chromosome 1 (1p) and the
long arm of chromosome 19 (19q; 1p/19q co-deletion) is prognos-
tic of a more favorable outcome than equivalent tumors without
this co-deletion (13–15). It is most commonly found in oligoden-
drogliomas or tumors with oligodendroglial features. The 1p/19q
co-deletion and ATRX mutations are generally mutually exclusive,
ATRX mutations being markers for astrocytic lineage tumors (16).
Mutations in IDH1/2 are also strongly associated with a dis-
tinct epigenetic signature. Mutant IDH1 and IDH2 alter glioma
metabolism, favoring the reduction of α-ketoglutarate to 2-
hydroxyglutarate (2-HG) (17), which in turn inhibits DNA and
histone demethylases and establishes a glioma-CpG island hyper-
methylator phenotype (G-CIMP) (5), featuring hypermethylation
at a large number of loci. The combination of IDH mutation,
1p/19q co-deletion and G-CIMP is prognostic of a favorable out-
come for anaplastic oligodendroglial tumors and predictive of
chemotherapy response (14, 15). IDH -mutant human gliomas
also have reduced levels of hypoxia-inducible factor (HIF) 1α
and the glycolytic enzyme lactate dehydrogenase A (LDHA)
(18). This deficit in glycolytic ability may also contribute to
the slower growth of IDH -mutant tumors and their improved
prognosis.
Most IDH mutated glioblastomas feature a proneural tran-
scriptional profile, including a high frequency of TP53 mutations
and amplification of PDGFRA (5). In contrast IDH-wildtype
glioblastoma tends to be subclassified into mesenchymal, classical,
and neural transcriptional subtypes. Upon recurrence, proneural
tumors shift toward a more aggressive mesenchymal phenotype,
enriched for expression of mesenchymal markers including chiti-
nase 3-like 1 (CHI3L1 or YKL40), CD44 and signal transducer and
activator of transcription 3 (STAT3) (6).
Colman et al. developed a robust 9-gene expression assay (now
a proprietary test called DecisionDx-GBM®) with the ability to
discriminate between glioblastoma patients with a more favor-
able outcome, associated with high-level expression of proneural
genes, and those with a poor outcome, with enriched expression of
mesenchymal and angiogenesis genes (19). Prognostic subgroups
are identified by profiling tumor RNA extracted from formalin-
fixed paraffin embedded (FFPE) tissue blocks and gene expression
levels converted to a metagene score, using a proprietary algo-
rithm. Multivariate analyses show that this 9-gene prognostic score
is a stronger predictor of overall outcome and progression-free
survival than other clinically significant variables, including age,
Karnofsky performance score (KPS), and MGMT. This 9-gene
expression assay independently predicts response to standard first
line therapy and has been used to prognostically stratify patients
and as a secondary endpoint in two clinical trials (20). However,
its lack of validation in larger independent patient cohorts means
that it has not been integrated into routine clinical testing.
MGMT promoter methylation
The current standard treatment for newly diagnosed glioblastoma
involves surgery and radiation, in conjunction with the alkylating
agent temozolomide (Stupp regimen), achieving a median survival
of 14.6 months (21). Response to temozolomide is mediated by
MGMT, encoding a DNA repair enzyme involved in the repair of
cytotoxic adducts produced by this alkylating agent. Hypermethy-
lation or epigenetic silencing of the MGMT disables DNA repair
capacity, rendering cells more sensitive to treatment (7). MGMT
promoter methylation is a common feature of IDH1/2 mutant/G-
CIMP positive glioma, however, is less prevalent in G-CIMP
negative tumors, such as primary glioblastoma, where MGMT
methylation occurs in approximately 40% of cases (22–24).
Several clinical trials, including the landmark studies by Stupp
and Hegi have shown that a methylated MGMT promoter is
an independent predictor of response to therapy and outcome
(21, 25–28). Patients with a methylated MGMT promoter exhib-
ited a 6.4-month survival benefit following concurrent treatment
with temozolomide and radiotherapy, compared to cases receiv-
ing radiotherapy alone (25), whereas the benefit for unmethylated
cases was less than 1 month (25). The NOA-08 and Nordic clini-
cal trials in elderly patients presenting with primary glioblastoma
have also shown that a methylated MGMT promoter is predictive
and prognostic in response to therapy (29, 30). The Nordic study
found that patients more than 60 years of age with methylated
MGMT gained an overall survival benefit following temozolomide
therapy, whereas methylation status did not correlate with overall
survival following radiotherapy (30). In the NOA-08 trial, patients
more than 65 years of age with methylated MGMT and a favorable
Karnofsky performance status similarly showed a greater overall
survival benefit following dose dense temozolomide therapy than
patients with unmethylated MGMT (29).
However, the use of MGMT methylation as a predictive
and prognostic biomarker in the routine clinical environment
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is not straightforward. Some patients with methylated MGMT
do poorly, and occasionally patients with unmethylated MGMT
have prolonged survival. This is likely due to additional mole-
cular changes. For example, it has recently been reported that
MGMT methylation status was only predictive in glioblastoma
cases with a classical transcriptional gene signature (7). There is
also evidence that defects in the mismatch repair (MMR) path-
way can confer increased resistance to temozolomide indepen-
dent of MGMT methylation status (31) with mutations in mutS
homolog 6 (MSH6) (32) and aberrant expression of MMR proteins
MSH6, mutS homolog 2 (MSH2), PMS2 postmeiotic segregation
increased 2 (PMS2), and mutL homolog 1 (MLH1) reported in
some glioblastoma specimens (33, 34). The lack of correlation
between MGMT status and treatment response in some cases may
be related to technical aspects of current analytical assays. Differ-
ences in the efficiency of the initial bisulfite conversion step and
also the region of the MGMT promoter selected for methylation
analysis may contribute to variability in MGMT results. Ever-
hard et al. performed a comprehensive study of CpG islands with
the MGMT promoter, correlating methylation status with MGMT
mRNA levels in 54 glioma specimens (35). This analysis identified
6 out of the 52 CpG sites as having the strongest correlation with
MGMT expression (p< 0.0001), indicating that methylation at
some sites may be more informative than others. MGMT expres-
sion may be induced by glucocorticoids (36), cAMP and protein
kinase C activators, and radiation to a moderate extent (37, 38).
Detection of MGMT expression by immunohistochemistry has
proved unreliable in predicting response (25, 39, 40).
EGFR amplification/truncation
EGFR is an attractive therapeutic target in glioblastoma, with
gene amplification noted in 40–60% of patients (1, 41, 42). A
constitutively active mutation of EGFR (EGFRvIII ) is found in
20–30% of glioblastomas and typically occurs in the presence
of over-expression (amplification) of the wild type transcript.
EGFRv111 is an in-frame genomic deletion of exons 2–7 result-
ing in a truncated protein with constitutive tyrosine kinase activity,
pro-oncogenic effects, and increased chemotherapeutic and radio-
therapy resistance. It is an independent marker of poor prognosis
in glioblastoma (42–44).
EGFR alterations increase cell signaling through mul-
tiple pathways, including the phosphatidylinositol-3-kinase
(PI3K)/Akt/mTOR pathway, and ultimately accelerate tumor
growth and progression. However, attempts to block EGFR signal-
ing in the clinic using small molecule inhibitors, such as erlotinib
and gefitinib, or monoclonal antibodies, such as cetuximab have
been largely unsuccessful, even after molecular preselection of
patients (45). An alternate strategy targeting EGFRv111 with a
vaccine (Rindopepimut) (46) is currently in Phase 3 clinical trials
for patients with newly diagnosed (ACT IV) and with relapsed
(ReACT) EGFRv111-positive glioblastoma following promising
phase II trials (47, 48).
Focal homozygous deletion of cyclin-dependent kinase inhibitor
2A (CDKN2A) is a frequent finding in EGFR amplified tumors
and these, together with the EGFRvIII, are features of the clas-
sical transcriptional subtype of glioblastoma (5). More recently,
the presence of activating telomerase reverse transcriptase (TERT)
promoter mutations have been reported in over 80% of primary
glioblastomas. In this cohort, EGFR amplification occurred only
in TERT -mutated tumors (49).
LIMITATIONS OF SINGLE-BIOPSY BASED DIAGNOSIS IN
GLIOBLASTOMA
Despite the major advances in the molecular profiling of glioblas-
toma, improvements to patient outcome overall have been modest.
Patient stratification and treatment have generally been performed
on the basis molecular biomarkers present in a single tumor spec-
imen. However, this approach may be too simplistic, as recent
studies have unraveled yet further layers of complexity, with strik-
ing molecular heterogeneity also present within individual tumor
specimens. Sottoriva et al. (50) employed a novel fluorescence-
guided multiple sampling approach to collect spatially distinct
tumor fragments from 11 glioblastomas, demonstrating the pres-
ence of multiple transcriptional tumor subtypes within the same
tumor mass (50). Spatial heterogeneity in glioblastoma not only
confounds histopathological classification but can also make treat-
ment decisions based on samples obtained from limited areas
difficult, especially as we enter the realm of personalized med-
icine and targeted therapies (2, 51, 52). There is also evidence
of temporal heterogeneity, with selective expansion or regression
of particular tumor cell subpopulations resulting from various
treatments (53).
The sampling of glioma presents a challenge unique to brain
tumors (54–56). Extracranial tumors can usually be resected en-
bloc to preserve the geographical map from which spatially distinct
tumor areas can be characterized and tumor margins and draining
lymph nodes examined to assess extent of disease. Some gliomas
are located in eloquent areas limiting sampling to a single biopsy.
Larger gliomas are generally resected in a piecemeal fashion in
order to minimize damage to surrounding brain and preserve
function and quality of life of the individual. Most surgery is
guided by gadolinium enhanced MRI scans. High-grade tumors
are usually resected up to and including the macroscopically
abnormal margin or to the area of contrast enhancement on T1
weighted MRI. It is well known, however, that aggressive infiltrat-
ing malignant cells lie well beyond this definable margin (54–56).
Newer techniques using fluorescent dyes such as 5-aminolevulinic
acid (ALA) potentially allow surgeons to identify areas of resid-
ual high-grade tumor at surgical margins making it possible to
remove more tumor, prolonging patient progression-free survival
(57).Using newer guidance technology may be able to separate
these tumors spatially for analysis and potentially provide better
guides to therapy. However, it is not clear from which location and
how many biopsies constitute a bona fide representative sample.
The co-existence of genetically divergent tumor cell clones may
lead to a misinterpretation of the overall genetic tumor landscape
if only a single sample is utilized.
TUMOR HETEROGENEITY
THEORIES OF TUMOR HETEROGENEITY
There are a number of theories regarding tumor evolution
and the generation of heterogeneous tumor cell subpopulations
(Figure 2). In the Darwinian theory of clonal evolution and nat-
ural selection, successive waves of tumor cells acquire genetic
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FIGURE 2 | Glioblastoma tumor heterogeneity and implications for
patient management. Tumor evolution and tumor heterogeneity may be
promoted by clonal evolution, cancer stem cells and interclonal
cooperativity. (A) According to the theory of clonal evolution, somatic
alterations affecting the initial cell of origin give rise to multiple cancer
clones, with different sensitivity to therapy and ability to survive and
proliferate. These tumor cell clones are genetically unstable, undergoing
successive waves of genetic alterations, and clones with the most
aggressive phenotype are favored. For example, only the MGMT
methylated cells sensitive to temozolomide (TMZ) disappear following
TMZ treatment. (B) In contrast, according to the cancer stem cell theory,
only a single subset of cells, known as cancer stem cells (CSC), possess
the ability to self-renew, continuously proliferate and give rise to clones of
variable genetic profiles, and are inherently resistant to therapy. (C) The
theory of interclonal cooperativity suggests that tumor evolution and
heterogeneity is promoted by interactions between tumor cell clones and
their microenvironment, with immune/stromal factors influencing
malignant progression. Significant clonal diversity within tumor specimens
may explain the failure of molecularly targeted therapies in glioblastoma
patients.
changes, some of which convey a proliferative advantage (58).
Selection and proliferation of therapy resistant clones lead to
tumor progression and resistance to therapy (59). Such branched
tumor evolution underscores the importance of targeting ubiq-
uitous alterations in the trunk of the phylogenetic tree (60). In
this theory, “driver mutations” allow the progression of a can-
cer, whereas “passenger mutations” are neutral or only slightly
deleterious (61). More recently, with the use of high-resolution
“next-generation” sequencing platforms, the definition of driver
events has been further refined to encompass “Mut-driver genes”
and “Epi-driver genes.” (62). Mut-driver genes tend to display
a non-random mutation pattern and are recurrently mutated at
the same amino acid position (for example, IDH ). Epi-driver
genes may be aberrantly expressed as a result of gene amplifi-
cation/loss or epigenetic alterations. These early somatic events
drive tumor growth and can be considered as “trunk events,” with
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branched separation of tumor subclones giving rise to tumor het-
erogeneity (63). This theory has been studied in colon cancer
where the evolution of genomic changes from benign polyps to
invasive carcinoma can be tracked from colonic biopsies. Study
of secondary glioblastoma, which usually develops from IDH
mutated low-grade lesions to invasive glioblastoma, may be pos-
sible, however primary glioblastoma appears to develop rapidly,
with some patients having had a normal MRI just months before
presentation. This group poses a particular challenge.
An alternative theory is the cancer stem cell theory, which pos-
tulates that only a subset of tumor cells possess the ability to
self-renew, continuously proliferate and give rise to clones contain-
ing variable genetic profiles, and the heterogeneity within a tumor
arises from proliferation of these genetically variable cancer stem
cells (64, 65). Genetically distinct cancer clones may originate in
specific anatomical locations, differing in neurochemistry, energy
metabolism, and surrounding tissue architecture (66). Gliomas are
thought to originate in the subventricular zone, which contains the
highest density of astrocyte-like stem cells, and may be more sus-
ceptible to malignant transformation (56). Distinct tumor clones
may harbor genetic alterations that promote invasion along blood
vessels and white matter tracts and tumor expansion in particular
cerebral lobes. The anatomical distribution of glioblastoma in the
brain is heterogeneous, occurring with the highest frequency in
the frontal lobe, followed by the temporal, parietal and occipital
lobes (66).
More recently a third theory, “interclonal cooperativity” has
emerged in which genetic subpopulations of tumor cell clones and
immune/stromal factors co-operate to create a favorable microen-
vironment (67–69). Feedback from the microenvironment drives
disease progression and a malignant phenotype. The complex
tumor stroma, consisting of reactive astrocytes, microglial cells
and immune infiltrate, aberrant microvascular proliferation and
hypoxia, as well as cell populations of varying developmental
stages, may also enhance the proliferation of specific cancer sub-
clones. Specifically, the hypoxic perivascular niche has been shown
to be critical for the self-renewal of glioblastoma cancer stem-like
cells (70, 71), and may be important in driver of divergent tumor
evolution and treatment resistance.
Unlike other tumors, gliomas rarely metastasize outside the
brain and despite intense local radiotherapy,most commonly recur
at the site of origin. Whether these recurrent tumors arise from
incompletely resected primary tumor or distinct cancer clones
that have evolved in response to treatment or other factors, such
microenvironmental cues, is unknown. However, a recent whole
exome sequencing study of low grade glioma supports the con-
cept that recurrent disease originates from tumor cells present at
tumor initiation that subsequently drive evolution of the tumor
(72), with just under half of recurrent specimens sharing 50% of
mutations with the primary tumor sample.
EVIDENCE OF MOLECULAR INTRA-TUMORAL HETEROGENEITY IN
GLIOBLASTOMA
As described above, microscopic heterogeneity is a hallmark of
glioblastoma. The evolution of more detailed molecular investiga-
tion and their potential implication in treatment decision making
has resulted in the further verification of tumor heterogeneity at
the molecular level. Tumor development and evolution has also
been extensively investigated and Sottoriva et al. have demon-
strated tumor heterogeneity in tumor evolution (50). Further
to this, Meyer et al. by establishing in vitro functionally distinct
clonal populations from glioblastoma specimens, have demon-
strated the potential differential response to treatment of these
various clones (73).
Both intra-tumoral and temporal heterogeneity in MGMT
status have been reported in some (74) but not all (75) such
investigations in glioma. Several authors have also demonstrated
intra-tumoral heterogeneity of receptor tyrosine kinases (RTKs)
in gliomas (76–78). Snuderl et al. (76) identified intermingled
populations of tumor cells containing varying amplification of up
to three different RTK genes (EGFR, MET, and PDGFRA), all of
which were derived from a common precursor. Likewise, Szerlip
et al. (77) found that multiple RTKs were likely to be maintaining
distinct cell subpopulations. Little et al. (78) also observed a high
degree of variability in gene copy number of EGFR and PDGFRA
in individual cells across entire glioblastoma specimens.
More recently, Patel et al. performed single cell RNA sequencing
on 430 cells from five primary glioblastomas, documenting intra-
tumoral variation in the expression of a range of transcriptional
programs, including oncogenic signaling, proliferation, immune
response, and hypoxia (79).
CLINICAL IMPLICATIONS OF MOLECULAR HETEROGENEITY IN
GLIOBLASTOMA
Intra-tumoral heterogeneity has important implications for the
development of prognostic and predictive biomarkers and their
ability to guide personalized treatment regimens. Transcriptional
profiling of glioblastoma into molecular subtypes is based on the
average expression of genes across a sample irrespective of intra-
tumoral heterogeneity (80) and may limit the usefulness of prog-
nostic panels, such as DecisionDx-GBM®. Similarly, intra-tumoral
molecular heterogeneity may underlie discordance between pre-
dictive markers, such as MGMT and treatment response.
Intra-tumoral heterogeneity may also contribute to the fail-
ure of targeted therapies in these patients. Glioblastomas pos-
sess genetic alterations that target three core signaling pathways,
including the RTK/RAS/PI3K axis, p53/MDM2/MDM4 axis, and
RB/CDK4/INK4A axis (7). However, targeting of these pathways
with monotherapies (such as the first generation EGFR kinase
inhibitors gefitinib and erlotinib) has failed to achieve any signifi-
cant clinical benefit in the majority of patients (81, 82). Diversity
of tumor subclones within the same individual, together with poor
drug penetration and activation of other compensatory pathways
in response to RTK inhibition (83, 84) is likely to account for this
negative result. Molecular preselection of patients for clinical tri-
als is challenging and tumor-sampling methods need to consider
the regional diversity of tumor subclones. Technology is available
to sequence genetic material from FFPE tumor blocks, however,
information on the spatial orientation of specimens may not be
available (80). Treatment of patients with more than one agent, tar-
geting major clones may be possible but limited by drug toxicity
and the ability of agents to penetrate the blood brain barrier (80).
The development of new treatment strategies for recurrent
disease must consider temporal diversity of tumor clones, with
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molecular biomarkers assessed in recurrent tumor biopsies where
possible, since they may differ substantially from initial diagno-
sis. Tumors harbor a complex hierarchy of clones, the proportions
or dominance of which may change following therapy. Molecular
biomarkers that are prognostic/predictive at initial diagnosis may
not be informative at recurrence. For example, the TCGA tran-
scriptional subtypes were determined using a cohort of primary
biopsies and may not be robust classifiers of recurrent disease.
Monitoring of clonal dynamics during treatment and targeting
of drug resistance clones may significantly improve patient out-
comes. However, this may be difficult to implement in the clinic,
with extensive/serial debulking not an option for glioblastoma
patients. Serial measurements of circulating tumor DNA for tumor
specific markers such as EGFRv111 (85), and the use of imag-
ing modalities to non-invasively monitor molecular biomarkers
may allow clinicians to monitor clonal evolution and treatment
response.
Although major advances in sequencing approaches are
enabling tumor heterogeneity to be studied at unprecedented res-
olution, the interpretation of results is still evolving, with the
detection and the clinical significance of minor clones still in
question. For example, heterogeneity may in some cases lead to
treatment resistance. Clinically actionable mutations must be ver-
ified by independent analysis using an alternative technology, such
as Sanger sequencing (86); however, this technology is limited by
its sensitivity and may not detect important low frequency vari-
ants. Clinicians need to decide which mutations to prioritize for
the purpose of treatment design. Alternatively, a measure of sub-
clonal diversity, such as the Shannon index, which estimates the
total number of tumor subclones and the relatively frequency of
each clone, may itself may be a useful prognostic biomarker, as has
been shown in the case of esophageal adenocarcinoma (87).
CONCLUSION
Our increased knowledge of molecular alterations in glioblastoma
has improved patient diagnosis and identified many new potential
therapeutic targets. Treatments directed at these specific alter-
ations may improve patient outcomes and reduce toxicity. The
introduction of molecular testing into routine diagnostic pathol-
ogy will also enable clinicians to better stratify patients for clinical
trials, selecting those that may benefit from targeted therapy.
While molecular profiling allows us to explore in depth, the
biological characteristics of a tumor, performing this on a single
biopsy specimen may be overly simplistic and inadequately reflect
both the genomic landscape and overall behavior of a tumor. It is
being increasingly recognized that glioblastoma contain multiple
distinct populations of tumor cells with the potential to con-
vey survival advantage and resistance to therapy, and these may
be selected and enriched through successive cycles of treatment.
However, many trials are conducted in relapsed patients whose
tumors may have been altered by previous radiotherapy and alky-
lating agents which are known to cause additional mutations, with
molecular preselection based on their original pathology speci-
men. Intra-tumoral heterogeneity, together with the concomitant
activation of multiple oncogenic signaling pathways in glioblas-
toma, suggests that a single agent will be ineffective in treating
this disease. Importantly, next generation sequencing technology
may enable the identification of molecular alterations occurring
early in gliomagenesis, the so-called “driver events,” which may
represent better targets for the design of therapeutic regimes.
Glioblastoma poses some unique challenges to clini-
cians – tumor cells diffusely invade surrounding normal brain
parenchyma, making complete surgical resection impossible, and
the efficacy of therapeutic agents are often limited by the blood
brain barrier. Resampling of tumors following treatment is also
limited. The development of non-invasive imaging techniques,
such as those associated with PET scanning, and identifica-
tion of circulating tumor cells harboring molecular biomarkers
may enable clinicians to non-invasively monitor clonal dynamics
during treatment and the development of disease recurrence.
The link between glioblastoma molecular subtype and response
to treatment is still incompletely understood. While the answer
may be gleaned from the molecular analysis of multiple biopsies
at each initial and subsequent resection, the use of such informa-
tion is still yet to prove beneficial in conveying any meaningful
survival advantage to those suffering from glioblastoma.
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